MERIAN GLOBAL INVESTORS UK Ltd Sells 174,517 Shares of Haemonetics Co. (HAE)

MERIAN GLOBAL INVESTORS UK Ltd lowered its stake in Haemonetics Co. (NYSE:HAE) by 40.0% during the first quarter, HoldingsChannel reports. The institutional investor owned 261,865 shares of the medical instruments supplier’s stock after selling 174,517 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd’s holdings in Haemonetics were worth $22,907,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of HAE. Norges Bank purchased a new stake in Haemonetics in the 4th quarter valued at approximately $80,411,000. Westfield Capital Management Co. LP lifted its stake in Haemonetics by 144.3% in the 4th quarter. Westfield Capital Management Co. LP now owns 709,952 shares of the medical instruments supplier’s stock valued at $71,031,000 after buying an additional 419,359 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Haemonetics by 40.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 709,853 shares of the medical instruments supplier’s stock valued at $81,335,000 after buying an additional 203,656 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Haemonetics in the 4th quarter valued at approximately $20,326,000. Finally, Emerald Advisers LLC purchased a new stake in Haemonetics in the 4th quarter valued at approximately $12,867,000. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

In other Haemonetics news, CEO Christopher Simon sold 57,587 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $94.51, for a total transaction of $5,442,547.37. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Michelle L. Basil sold 391 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $83.57, for a total value of $32,675.87. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,808 shares of company stock worth $5,920,731. Corporate insiders own 1.04% of the company’s stock.

A number of research firms recently issued reports on HAE. Zacks Investment Research lowered Haemonetics from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Barrington Research reaffirmed an “outperform” rating and issued a $116.00 target price (up previously from $112.00) on shares of Haemonetics in a research note on Wednesday, May 8th. TheStreet raised Haemonetics from a “c+” rating to a “b-” rating in a research note on Tuesday, May 7th. Raymond James raised Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a research note on Tuesday. Finally, ValuEngine lowered Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $118.60.

Shares of Haemonetics stock opened at $100.07 on Friday. Haemonetics Co. has a fifty-two week low of $80.24 and a fifty-two week high of $117.56. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of 41.87, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.62 and a current ratio of 2.44.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.06. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The company had revenue of $249.30 million for the quarter, compared to analyst estimates of $250.62 million. During the same quarter in the prior year, the company posted $0.43 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Analysts expect that Haemonetics Co. will post 2.91 earnings per share for the current fiscal year.

WARNING: This piece was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/18/merian-global-investors-uk-ltd-sells-174517-shares-of-haemonetics-co-hae.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: Do stock splits help investors?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.